Transgenic model evaluation II (Aspartame): Target Organs and Levels of Evidence for GMM-01
Toxicology Studies of Aspartame (CASRN 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129-Cdkm2atn1Rdp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Feed Studies)
| Chemical (Study Title) CASRN | Peer Review Date | Primary Uses | Route/Exposure Levels | Study Laboratory |
|---|---|---|---|---|
| Transgenic model evaluation II (Aspartame) 22839-47-0 | 05/22/2003 | Artificial sweetener to be tested using various strains of transgenic animal models. | Dosed-Feed 0, 3,125, 6,250, 12,500, 25,000 or 50,000 ppm; 15 animals/sex/dose | BioReliance, Inc |
| Male Tg.AC Hemizygous Mice | Female Tg.AC Hemizygous Mice | |
|---|---|---|
| 39 Weeks | 39 Weeks | |
| Neoplastic Lesions | None | None |
| Non-Neoplastic Lesions | None | None |
| Male p53 Haploinsufficient Mice | Female p53 Haploinsufficient Mice | |
|---|---|---|
| 39 Weeks | 39 Weeks | |
| Levels of Evidence | No Evidence | No Evidence |
| Neoplastic Lesions | None | None |
| Non-Neoplastic Lesions | None | None |
| Male Cdkn2a Deficient Mice | Female Cdkn2a Deficient Mice | |
|---|---|---|
| 39 Weeks | 39 Weeks | |
| Levels of Evidence | No Evidence | No Evidence |
| Neoplastic Lesions | None | None |
| Non-Neoplastic Lesions | Liver: hepatocyte, cytoplasmic periportal vacuolization | None |